| E2F3 loss leads to an increase in the rate of tumor initiation. Finally, analysis of Rb(+/-); E2f3(+/-) mice shows that this tumor-suppressive function of E2F3 is dose dependent. | None |
| E2F3a has a unique apoptotic activity and lacks the tumor suppressive property of E2F1 in this model system. | None |
| deregulated expression of E2F3a causes DNA damage under physiological conditions and indicate that the ATM-dependent response to this damage is important for the induction of apoptosis and tumor suppression | None |
| oncogenic activities of E2F1 and E2F3 in ErbB2- or Myc-triggered mammary tumorigenesis, and a tumor suppressor role of E2F2 in Myc-mediated mammary tumorigenesis | None |
| miR-660, as a tumor-suppressive gene, was significantly decreased in gastric cancer and directly bound to oncogene E2F3 to inhibit E2F3 expression. | gastric, |
| Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. | None |
| Pumilio facilitates miRNA regulation of the E2F3 oncogene. | None |
| oncogenic activities of E2F1 and E2F3 in ErbB2- or Myc-triggered mammary tumorigenesis, and a tumor suppressor role of E2F2 in Myc-mediated mammary tumorigenesis | None |